Introduction
Hypoxic exposure induces systemic stress, impaired exercise capacity, and gut-related injury. Previous multi-omics analysis and literature evidence suggested that butyrate may be a key beneficial metabolite against hypoxia-associated intestinal damage. As butyrate is mainly produced by gut microbial fermentation of dietary substrates, synbiotic modulation of intestinal butyrate metabolism may represent a promising strategy for mitigating hypoxia-related injury.
Aims & Methods
This study aimed to develop a synbiotic targeting intestinal butyrate metabolism and evaluate its protective effects in hypoxia-exposed mice. Nine food-grade probiotic strains were screened, and in vitro butyrate production was assessed by gas chromatography. The synbiotic comprising three probiotic strains and a prebiotic was developed. Eight-week-old male C57BL/6 mice were randomly assigned to six groups (n=8 per group): normoxic control (C; normoxia + sterile saline), hypoxia model (M; hypoxia + sterile saline), positive control (P; hypoxia + Hongyi capsule, mainly Rhodiola, 300 mg/kg), synbiotic (T1; hypoxia + synbiotic, 1×10⁹ CFU/ml), synbiotic plus positive control (T2; hypoxia + symbiotic + Hongyi capsule), and sodium butyrate (B; hypoxia + sodium butyrate, 150 mmol/L). After 7 days of normoxic pretreatment, interventions continued for another 7 days; all groups except C were exposed to 10% oxygen. Body weight was recorded daily. SpO₂, heart rate, and respiratory rate were monitored using the MouseOx Plus oximeter. Rotarod and open-field tests assessed motor function and anxiety-like behavior. Fecal short-chain fatty acids (SCFAs) were quantified.
Results
The three-strain synbiotic formulation was selected from the screened strains, and cellobiose increased butyrate production by 26.6% versus the unsupplemented formulation. Under hypoxia, body weight declined in all exposed groups, with the most pronounced loss in the M group, while the T1 group showed milder weight loss and earlier recovery. After 24 h of hypoxic exposure, SpO₂ in the M group decreased to 91.7 ± 1.8%, compared with 96.6 ± 0.5% in the C group (P < 0.001), accompanied by increased heart rate and respiratory rate (M vs. C: 685.0 ± 20.4 vs. 651.2 ± 8.0 bpm and 186.4 ± 14.1 vs. 169.6 ± 6.7 BrPM). In the rotarod test, motor performance was significantly impaired in the M group compared with the C (P=0.017); this impairment was significantly ameliorated in the P group (P=0.039), whereas no significant improvement was observed in the T1 group. In the open-field test, total distance traveled was significantly reduced in the M group compared with the C (P=0.0052), whereas it was significantly increased in the T1 group (P=0.0083) and B group (P=0.0057) versus the M group. Time in the center zone also tended to increase in the T1 and B groups, although without statistical significance, suggesting partial improvement of hypoxia-induced suppression of spontaneous activity and a potential trend toward reduced anxiety-like behavior. Fecal butyrate levels were significantly lower in the M group than in the C group (P = 0.0078) and were significantly restored by synbiotic treatment (P = 0.0484).
Conclusion
This synbiotic was designed to modulate intestinal butyrate metabolism, with cellobiose promoting butyrate production. It restored fecal butyrate levels and partly mitigated body weight loss, locomotor impairment, and anxiety-like behavior in hypoxia-exposed mice. These findings support the gut microbiota-butyrate axis as a promising intervention target for hypoxia-related host dysfunction.